Follow The Filings

RNA Atrium Therapeutics Inc.

Health Care, filed as ATRIUM THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 1 Owner
  • Max 0.3%
  • $1.7M
  • 1 new 1 exit

In 2026 Q2 Nathan Fischel opened a position in Atrium Therapeutics, while Farallon Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel New 0.33%

Who owns RNA

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.33% New 0.33% 128,000 $1.7M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 0.03% Exit −0.03% 349,360 $4.7M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RNA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RNA insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 8 share withholdings for taxes and 6 stock grants.

SEC filings

Recent issuer filings from EDGAR, 17 shown.

Filed Form Detail Links
8-K 8.01,9.01
8-K/A 8.01
8-K 1.01,3.02,8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
8-K 8.01,9.01
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
SCHEDULE 13G —
8-K 1.01,5.01,5.02,9.01
8-K 7.01,9.01

Financials

US-GAAP annual figures, as tagged in Form 10-K

Newly public, no 10-K financials yet. See the 10-Q.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.